MedTrace Logo

Efficacy and Safety of a 1064-nm Nd:YAG Picosecond Laser Versus a 1927-nm Fractional Laser for Atrophic Acne Scars.

NCT07153679 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-09-04

No results posted yet for this study

Summary

Atrophic acne scars are common disfiguring skin problems, especially in the Asian population prone to Post-inflammatory Hyperpigmentation (PIH), and their treatment is highly challenging. 1064 nm microlens array picosecond laser (P-MLA) based on optomechanical effect and 1927 nm segmented thulium laser (FTL) based on photothermal effect are two emerging therapeutic techniques, but there is a lack of strict clinical evidence for direct comparison in the Asian population. This study aims to directly compare the clinical efficacy, safety and tolerability of 1064 nm P-MLA and 1927 nm FTL in the treatment of atrophic acne scars in the Asian population through a randomized, half-face controlled, evaluator blind trial.

Conditions

  • Acne Scar
  • Acne Scars - Atrophic

Interventions

DEVICE

1064-nm Nd:YAG Picosecond Laser

Treatment was performed using 1064 nm Nd:YAG microlens array picosecond laser (Picocare 450, WONTECH, Daejeon, South Korea). Received three treatments, with a 4-week interval between each treatment.

DEVICE

1927-nm Fractional Thulium Laser

Treatment was performed using 1927-nm thulium fractional laser (Lavieen, WONTECH, Daejeon, South Korea). Received three treatments, with a 4-week interval between each treatment.

Sponsors & Collaborators

  • Second Affiliated Hospital of Xi'an Jiaotong University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-05-01
Completion
2021-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07153679 on ClinicalTrials.gov